CDT CDT Equity Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1896212 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-70.5%
TTM EPS YoY199.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-49.2%
ROA-41.4%
ROIC (approx.)-37.1%
Asset turnover—
Leverage & solvency
Liabilities / assets14.1%
Debt / equity0.00x
Current ratio0.20x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio-29.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $5.05M | $3.38M | $90,000 | $37,000 |
| SG&A expense | $31.70M | $12.04M | $5.17M | $3.05M |
| Operating income | -$36.76M | -$15.42M | -$5.26M | -$3.16M |
| Interest expense | $200,000 | $32,000 | $0 | $100,000 |
| Pretax income | -$39.22M | -$17.80M | -$536,000 | $773,501 |
| Income tax | — | — | — | $374,862 |
| Net income | -$39.22M | -$17.80M | -$535,000 | -$4.89M |
| EBITDA | — | -$15.41M | — | — |
| EPS (basic) | -1,177.89 | -61,598.62 | -0.79 | -0.13 |
| EPS (diluted) | -1,177.89 | -61,598.62 | -8.92 | -0.13 |
| Weighted avg. shares (diluted) | 33,300 | 289 | 678,939 | 37.45M |
| Balance sheet | ||||
| Cash & equivalents | $1.51M | $554,000 | $4.23M | $345,777 |
| Short-term investments | — | $600,000 | $4.20M | — |
| Current assets | $4.38M | $2.71M | $5.73M | $646,639 |
| PP&E, net | $269,000 | $40,000 | — | — |
| Intangibles | — | — | — | $5,000 |
| Total assets | $5.65M | $4.19M | $7.22M | $5,000 |
| Current liabilities | $12.82M | $10.74M | $1.80M | $4.18M |
| Total liabilities | $12.82M | $10.99M | $7.68M | $10.09M |
| Shareholders' equity | -$7.17M | -$6.79M | -$457,000 | -$10.09M |
| Shares outstanding | 18 | 461 | 738,295 | 64.63M |
| Cash flow statement | ||||
| Operating cash flow | -$15.55M | -$9.68M | -$7.72M | -$2.27M |
| Capital expenditure | — | $51,000 | — | — |
| Free cash flow | — | -$9.73M | — | — |
| Investing cash flow | -$808,000 | -$43,000 | $725,000 | -$183,000 |
| Financing cash flow | $17.42M | $6.07M | $10.93M | $2.45M |
| Depreciation & amortization | — | $10,000 | — | — |
| Stock-based compensation | $2.18M | $1.63M | $199,000 | — |
| Share buybacks | $106,000 | — | — | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.